Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis

  • Antje Neubert
  • Kristin Lukas
  • Thomas Leis
  • Harald Dormann
  • Kay Brune
  • Wolfgang Rascher
Pharmacoepidemiology and Prescription

Abstract

Purpose

This study aims to describe the drug use on a Neonatal Intensive Care Unit (NICU) at a University Children’s Hospital in Germany, to investigate the licensing status of the drugs used and to conclude critical areas in neonatal intensive care to support prioritisation of future research.

Methods

An 11-month, prospective cohort study was conducted on the NICU at the University Children’s Hospital Erlangen, Germany. All products prescribed during the study period were analysed whether or not the SPC contains information on term and preterm neonates.

Results

A total of 183 patients (102 male) with a mean gestational age of 33.6 weeks (minimum = 24, maximum = 42) were included. The mean length of hospitalisation was 19.4 days (minimum = 2, maximum = 167). On average, patients received 11.1 drugs (minimum = 0, maximum = 46). The majority of prescriptions were accounted for by antibiotics (n = 515), which were received by 90% of all patients, followed by CNS drugs (n = 448) and respiratory drugs (n = 306). Of all the different drugs prescribed (n = 102) only 38% had information regarding their use in patients aged less than 1 month in their SPC. Analgesics and cardiovascular drugs were prescribed frequently, but without having information for use in neonates. Seventy percent of all patients and 100% of very preterm infants received at least one of these drugs.

Conclusions

Treatment strategies on a preterm intensive care unit are complex and little information is available for the drugs used. Analgesics and cardiovascular drugs are of major concern. Efforts will have to be made to conduct well-designed and powered studies in this vulnerable population.

Keywords

Drug utilisation Preterm Neonates Neonatal intensive care unit Unlicensed Off-label 

References

  1. 1.
    Du W, Warrier I, Tutag Lehr V, Salari V, Ostrea E, Aranda JV (2006) Changing patterns of drug utilization in a neonatal intensive care population. Am J Perinatol 23:279–285CrossRefPubMedGoogle Scholar
  2. 2.
    Saigal S, Doyle LW (2008) An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 371:261–269CrossRefPubMedGoogle Scholar
  3. 3.
    Lindner U, Hilgendorff A, Frey G, Gortner L (2008) Drug utilisation in very preterm infants: any changes during the past decade? Klin Padiatr 220:238–242CrossRefPubMedGoogle Scholar
  4. 4.
    Warrier I, Du W, Natarajan G, Salari V, Aranda J (2006) Patterns of drug utilization in a neonatal intensive care unit. J Clin Pharmacol 46:449–455CrossRefPubMedGoogle Scholar
  5. 5.
    European Commission (2006) Regulation (EC) No. 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use. European Commission, BrusselsGoogle Scholar
  6. 6.
    Neubert A, Planner C, Cranswick N (2008) The new European regulation on pediatric medicines: safety and ethics perspectives. Paediatr Drugs 10:147–149CrossRefPubMedGoogle Scholar
  7. 7.
    Senate and House of Representatives of the United States of America (2003) Pediatric Research Equity Act of 2003Google Scholar
  8. 8.
    World Health Organisation (2007) Making medicines child size. World Health Organisation, GenevaGoogle Scholar
  9. 9.
    Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, Quaranta R, Dell’Erba AS (2007) Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 29:361–367CrossRefPubMedGoogle Scholar
  10. 10.
    Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88:965–968CrossRefPubMedGoogle Scholar
  11. 11.
    WHO Collaborating Centre for Drug Statistics Methodology. Anatomical-Therapeutical-Chemical (ATC) Classification—Index and Guidelines. World Health Organisation, GenevaGoogle Scholar
  12. 12.
    Daniell AJ, Darlow BA (1989) Audit of drug usage in a regional neonatal intensive care unit. Aust Paediatr J 25:207–210PubMedGoogle Scholar
  13. 13.
    Lesko SM, Epstein MF, Mitchell AA (1990) Recent patterns of drug use in newborn intensive care. J Pediatr 116:985–990CrossRefPubMedGoogle Scholar
  14. 14.
    Gortner L, Bernsau U, Brand M, Hellwege HH, Hieronimi G, Jorch G, Reiter HL, Versmold H (1991) Drug utilization in very premature infants in neonatal intensive care units. Dev Pharmacol Ther 17:167–171PubMedGoogle Scholar
  15. 15.
    Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 80:F142–F144CrossRefPubMedGoogle Scholar
  16. 16.
    Turner MA, Lewis S, Field D (2008) Priorities in neonatal medicines research: a scoping exercise, Abstract, Biannual Meeting ESDPP, RotterdamGoogle Scholar
  17. 17.
    O’Donnell CP, Stone RJ, Morley CJ (2002) Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 110:e52CrossRefPubMedGoogle Scholar
  18. 18.
    Clark RH, Bloom BT, Spitzer AR, Gerstmann DR (2006) Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 117:1979–1987CrossRefPubMedGoogle Scholar
  19. 19.
    Gordon A, Jeffery HE (2005) Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database Syst Rev CD004501Google Scholar
  20. 20.
    Cunha GS, Mezzacappa FF, Ribeiro JD (2003) Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns. J Pediatr (Rio J) 79:550–556Google Scholar
  21. 21.
    Sweet DG, Halliday HL (2000) A risk-benefit assessment of drugs used for neonatal chronic lung disease. Drug Saf 22:389–404CrossRefPubMedGoogle Scholar
  22. 22.
    Stevens TP, Blennow M, Myers EH, Soll R (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev CD003063Google Scholar
  23. 23.
    Soll RF, Morley CJ (2001) Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev CD000510Google Scholar
  24. 24.
    Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev CD001456Google Scholar
  25. 25.
    Been JV, Zimmermann LJ (2007) What’s new in surfactant? A clinical view on recent developments in neonatology and paediatrics. Eur J Pediatr 166:889–899CrossRefPubMedGoogle Scholar
  26. 26.
    Hughes JL, McCall E, Alderdice F, Jenkins J (2006) More and earlier surfactant for preterm infants. Arch Dis Child Fetal Neonatal Ed 91:F125–F126CrossRefPubMedGoogle Scholar
  27. 27.
    Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C (2000) The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 7:143–147CrossRefPubMedGoogle Scholar
  28. 28.
    Knoeppel C, Klinger O, Soergel M, Seyberth HW, Leonhardt A (2000) Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern. Monatsschr Kinderheilkd 148:904–908CrossRefGoogle Scholar
  29. 29.
    European Medicine Agency (2008) Priority list of off-patent medicinal products for paediatric studies. EMEA, LondonGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Antje Neubert
    • 1
  • Kristin Lukas
    • 2
  • Thomas Leis
    • 2
  • Harald Dormann
    • 3
  • Kay Brune
    • 4
  • Wolfgang Rascher
    • 2
  1. 1.Centre for Paediatric Pharmacy Research, The School of Pharmacy and Institute of Child HealthUniversity of LondonLondonUK
  2. 2.Department of Paediatric and Adolescent MedicineFriedrich-Alexander University Erlangen-NurembergErlangenGermany
  3. 3.Department of Medicine 1Friedrich-Alexander-University Erlangen-NurembergErlangenGermany
  4. 4.Department of Experimental and Clinical Pharmacology and ToxicologyFriedrich-Alexander University Erlangen-NurembergErlangenGermany

Personalised recommendations